Related Experiment Video

Updated: May 7, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.3K

First IL-6-blocking drug nears approval for rare blood disorder

Sarah C P Williams

    Nature Medicine
    |October 9, 2013
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
    10:49

    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

    Published on: September 18, 2013

    17.5K
    Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
    08:17

    Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

    Published on: October 30, 2016

    20.9K

    Related Experiment Videos

    Last Updated: May 7, 2026

    Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
    06:07

    Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

    Published on: February 5, 2020

    5.3K
    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
    10:49

    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

    Published on: September 18, 2013

    17.5K
    Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
    08:17

    Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

    Published on: October 30, 2016

    20.9K

    Related Concept Videos

    FDA Approved Drugs: Changes to Approved Drugs01:26

    FDA Approved Drugs: Changes to Approved Drugs

    344
    Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
    344
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    619
    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
    619

    Articles linked to this work by shared authors, journal, and citation graph.

    Profile of C. Robin Buell.

    Proceedings of the National Academy of Sciences of the United States of America·2026

    Profile of Morris Moscovitch.

    Proceedings of the National Academy of Sciences of the United States of America·2026

    Profile of John P. Smol.

    Proceedings of the National Academy of Sciences of the United States of America·2026

    Profile of Helen M. Piwnica-Worms.

    Proceedings of the National Academy of Sciences of the United States of America·2026

    Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium.

    Nature medicine·2026

    Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial.

    Nature medicine·2026

    Induced pluripotent stem cells from discovery to translation.

    Nature medicine·2026

    CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.

    Nature medicine·2026

    A multi-faceted hospital-based intervention for intrapartum care in sub-Saharan Africa: a stepped-wedge cluster-randomized trial.

    Nature medicine·2026

    Recombinant shingles vaccination and the risk of cardiovascular events.

    Nature medicine·2026

    Long-term outcome of pediatric anti-complement factor H antibody-associated atypical hemolytic uremic syndrome receiving abbreviated plasma exchange: a retrospective study from a single center.

    Journal of nephrology·2026

    [Therapeutic apheresis in first-line treatment of hematological disorders - an evidence-based review].

    Therapeutische Umschau. Revue therapeutique·2026

    Same-day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony-stimulating factor mobilization.

    Transfusion·2026

    Platelet-erythrocyte complex production is exacerbated by histones and protected by small polyanion histone neutralizing compounds.

    Platelets·2026

    Changing the treatment paradigm in beta thalassemia.

    Folia medica·2026

    Noninvasive Thrombus Imaging in Patients With Ischemic Stroke.

    Circulation·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us